PET Evaluation of Recurrent Differentiated Thyroid Cancer
Conditions
Thyroid Neoplasms - Differentiated Thyroid Cancer
Conditions: official terms
Thyroid Diseases - Thyroid Neoplasms
Conditions: Keywords
Recurrent differentiated thyroid cancer, I124-PET/CT, FDG-PET/CT
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Not yet recruiting
Summary
After initial treatment of differentiated thyroid cancer patients (DTC) are followed by a blood test, a biomarker called thyroglobulin, in order to detect a possible recurrence. Nowadays patients are treated 'blindly' with high dose radioactive iodine to treat a suspected recurrence. However, the scan made after therapy to verify the effect of the treatment shows that in up to 50% the treatment could be considered as futile.

124I - a radioactive isotope - in combination with whole body PET became recently available for use in the follow-up of DTC. This could make it possible before the therapy with high dose radioactive iodine to determine the extensiveness of the disease and whether effect of the therapy could be expected. Additionally, recurrent DTC lesions that do not accumulate iodine can be found without the futile treatment with 131I. FDG-PET (another PET modality) is able to detect these lesions. The value of FDG-PET before 131I treatment however has not been tested.

The combination of these two diagnostic tools, 124I-PET and FDG-PET, has a potential to allow earlier and better restaging and selection for treatment
Detailed Description
Differentiated thyroid cancer (DTC) is the most frequent endocrine tumor, with an annual incidence per 100.000 individuals of 1 - 3 in men and 2 - 4 in women. In general DTC has a good prognosis, and only 6% of patients will die of their disease, but the prognosis is less favourable when the disease recurs after primary treatment.

Measurement of the tumor marker Thyroglobulin (Tg) in serum plays a pivotal role in the follow-up of differentiated thyroid cancer. Serum Tg should be undetectable in DTC patients following thyroid remnant ablation with radioactive iodine-131 (131I), and any detectable level signals the persistence of (neoplastic) thyroid tissue. A serum Tg cut-off level of ≥ 2 ng/ml following rhTSH is highly sensitive for identifying patients in whom persistent tumor may be found.

Historically the follow-up of patients with DTC included diagnostic planar scintigraphy with a low dose of 131I, but nowadays this is no longer recommended because of poor sensitivity. Instead, whole body scintigraphy after blind administration of high dose, 'therapeutic', 131I is recommended, both to diagnose and stage the potential recurrence, and to initiate its treatment. This strategy can be effective, but an estimated 38% - 50% of patients will have a negative post-therapeutic whole body scan and/or no objective therapy effect. These patients will have received a total body irradiation of 450 mSv and potentially will have suffered from side effects such as nausea, sialoadenitis, loss of taste, or reduced spermatogenesis. Also, the prolonged thyroid hormone withdrawal and subsequent hypothyroidism necessary for 131I therapy has major impact on quality of life with a majority of patients suffering from significant changes in physical, psychological, and social well-being. The high frequency of high dose 131I therapies from which patients do not derive any benefit but are exposed to its toxicity and potential adverse oncological effects, has led to a search for new diagnostic tools to improve the selection of patients before such treatment.

Historically, ultrasound of the neck is applied to detect local recurrence or regional lymph node metastases, and it allows direct biopsy to confirm the diagnosis. But ultrasound is limited to the neck only, and when it is negative in the presence of detectable Tg, a form of whole body evaluation is required.

Recently Iodine-124 (124I) became available as a novel radionuclide for whole body PET imaging in the follow-up of DTC, with a promising diagnostic accuracy and a considerably lower radiation exposure as compared to planar whole body scintigraphy after high dose 131I. Furthermore, recent experience has shown that 124I-PET images may be representative for the biodistribution and radiation dosimetry of subsequent treatment with high dose 131I. Thus, with the availability of 124I-PET, it might become possible to more accurately re-stage patients in a whole body procedure, perform dosimetry for subsequent 131I therapy and predict the outcome of the treatment.

At the same time, some recurrent DTC lesions do not accumulate iodine, which is correlated with tumor dedifferentiation and poor prognosis. Patients suspected of non-iodine accumulating DTC, so far only evident after futile blind 131I therapy, require restaging before local or systemic therapy may be installed. Metabolic PET imaging with the glucose analogon 18F-fluorodeoxyglucose (FDG), stimulated with rhTSH, has a high sensitivity for recurrent DTC in patients with detectable Tg and negative iodine scintigraphy, may correlate with a more aggressive tumor behaviour and poor prognosis, and is able to select patients for additional surgery or external beam radiotherapy. This technique is currently applied only when prior treatment and imaging with high dose 131I has proven to be ineffective. The value of FDG-PET before 131I treatment has not been tested.

The uptake of 124iodine and FDG are related to histopathological characteristics of tumor tissue, such as the resected primary tumor or metastases. 124I uptake is related to expression of the sodium iodine symporter (NIS), while FDG uptake is related to hexokinase-I (HKI) activity. The power of combined 124I-PET and FDG-PET for detection and characterization of DTC lesions has been suggested in proof of concept studies. The relation of these imaging findings and histopathological parameters (such as thyroglobulin, TTF1, Ki-67 and Cytokeratine-19 staining) and response to 131I treatment has not been elucidated in sufficiently large series.

Based on the characteristics of 124I-PET and FDG-PET, it is reasonable to assume that a combined strategy of imaging and histopathological evaluation at the time of suspected recurrence will yield adequate information on the disease stage prior to treatment with 131I, regardless of tumor dedifferentiation, with a potential impact on clinical decision making. This hypothesis needs proper testing, to increase fundamental knowledge about DTC and further improve treatment.

The multi-center design of this study requires a standard acquisition of the 124I-PET scans. Previously this was done for FDG-PET in the Netherlands, the so-called NEDPAS protocol. In order to compare the scans between the centers calibration and standardization of the 124I-PET scans prior to the start of the study will be done.

Additional to this objective the study aims to answer whether thyroid hormone withdrawal and rhTSH preparation for the 124I-PET results in different scan results.

In summary, high dose 131I treatment for recurrent DTC is effective in many cases, but the current blind approach also leads to overtreatment, delay, and unnecessary decrease in quality of life in a significant number of cases. As we have shown, a combination of diagnostic tests has a potential to allow earlier and better restaging and selection for treatment. The proposed trial aims to test the value and optimal implementation of these new tests, standalone and in combination, to derive parameters for a new personalised strategy for diagnosis and treatment of patients with (suspected) recurrent DTC.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients with a history of differentiated thyroid cancer

- After complete thyroidectomy and ablation of functional remnants with 131I.

- Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml.

- Ultrasonography of the neck performed < 2 months prior to inclusion.

Exclusion Criteria:

- Age < 18 years

- Pregnancy

- Incapacitated subjects

- Contrast enhanced CT performed < 4 months prior to inclusion

- I-131 therapy performed < 12 months prior to inclusion

- Indication for other therapy modality (ie. surgery in case of a positive ultrasonography, radiotherapy, embolization or chemotherapy)
Locations
Rijnstate Hospital
Arnhem, Gelderland, Netherlands
Status: Not yet recruiting
Contact: Vanessa JR Schelfhout, MD - +31 88 005 8888 - VSchelfhout@rijnstate.nl
UMC St. Radboud Nijmegen
Nijmegen, Gelderland, Netherlands
Status: Not yet recruiting
Contact: Martin Gotthardt, MD PhD - +31243611111 - m.gotthardt@nucmed.umcn.nl
Bernard Verbeeten Institute
Tilburg, Noord-Braband, Netherlands
Status: Not yet recruiting
Contact: Arjen B van Dijk, MD - +31 13 5947715 - dijk.v.a@bvi.nl
Jeroen Bosch Hospital
Den Bosch, Noord-Brabant, Netherlands
Status: Not yet recruiting
Contact: Corneline J Hoekstra, MD PhD - +31 73 553 2690 - C.Hoekstra@jbz.nl
Catharina Hospital
Eindhoven, Noord-Brabant, Netherlands
Status: Not yet recruiting
Contact: Dyde Huysmans, MD PhD - +31 40 239 9111 - dyde.huysmans@catharinaziekenhuis.nl
Medical Center Alkmaar
Alkmaar, Noord-Holland, Netherlands
Status:
St. Lucas Andreas Hospital
Amsterdam, Noord-Holland, Netherlands
Status: Not yet recruiting
Contact: Farida Sivro, MD - +31 20 510 8877 - f.sivro@nki.nl
VUmc Medical Center
Amsterdam, Noord-Holland, Netherlands
Status: Not yet recruiting
Contact: Otto S Hoekstra, MD PhD - +31 20 4444214 - os.hoekstra@vumc.nl
Medical spectrum Twente
Enschede, Overijssel, Netherlands
Status: Not yet recruiting
Contact: Wieger I de Bruin, MD - +31 53 4872088 - w.debruin@mst.nl
Isala Clinics
Zwolle, Overijssel, Netherlands
Status: Not yet recruiting
Contact: Piet L Jager, MD PhD - +31 38 424 7909 - p.l.jager@isala.nl
Meander Medical Center
Amersfoort, Utrecht, Netherlands
Status: Not yet recruiting
Contact: John MH de Klerk, MD PhD - +31338505050 - jmh.de.klerk@meandermc.nl
St. Antonius hospital
Nieuwegein, Utrecht, Netherlands
Status: Not yet recruiting
Contact: Jules Lavalaye, MD PhD - +31 88 320 3000 - j.lavalaye@antonius.net
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands
Status: Not yet recruiting
Contact: Bernies van der Hiel, MD PhD - +31715263475 - b.van_der_hiel@lumc.nl
University Medical Center Groningen
Groningen, Netherlands
Status: Not yet recruiting
Contact: Adrienne H Brouwers, MD PhD - +31503611319 - a.h.brouwers@ngmb.umcg.nl
University Medical Center Utrecht
Utrecht, Netherlands
Status: Not yet recruiting
Contact: Bart de Keizer, MD PhD - +31 88 755 5555 - b.dekeizer@umcutrecht.nl
Start Date
August 2012
Completion Date
January 2016
Sponsors
The Netherlands Cancer Institute
Source
The Netherlands Cancer Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page